Abstract:Background This study aimed to evaluate the visual and morphological outcomes of intravitreal anti-VEGF therapy and the recurrence for idiopathic choroidal neovascularization (ICNV). Methods This retrospective study included 35 patients (35 eyes) with ICNV from July 2012 to October 2017. All patients received 1 intravitreal anti-VEGF injection followed by pro re nata injections until there was no sign of ICNV activity. This was defined as the first follow-up period. To evaluate ICNV recurrence, we continued to follow-up 27 of the 35 patients for at least 2 years after the initial diagnosis, and the longest follow-up period was 5 years. Additional injection was performed when ICNV recurred. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded and morphological improvement in optical coherence tomography (OCT) was assessed. Parameters that affect prognosis and recurrence were analysed. Results The mean follow-up period was 168.0 ± 34.82 weeks. Mean BCVA improved from 56.20 ± 14.13 letters at baseline to 73.31 ± 12.57 letters ( P <0.01); Mean CRT decreased from 353.6 ± 98.70 μm at baseline to 273.1 ± 53.56 μm ( P < 0.001) at the end of the first follow-up period. Better baseline BCVA indicated a better morphological improvement ( P = 0.026) in OCT: the lesion had completely subsided with recovery of the foveal contour. Those with high baseline BCVA (more than 60 letters) showed significant resolution of CNV lesions ( P = 0.036). ICNV recurred in six patients (22.2%), 1 of whom experienced 2 recurrences. The mean timing of recurrence was 90.83 ± 49.02 weeks after diagnosis. There was no significant correlation between ICNV recurrence and the morphological improvement ( P = 0.633). The final BCVA in patients with recurrence did not differ from that in patients without recurrence ( P = 0.065). Conclusions Intravitreal anti-VEGF therapy on a pro re nata basis was effective for treating ICNV. High baseline BCVA indicated a better prognosis. Re-treatment with anti-VEGF could effectively lead to resolution of recurrent ICNV. Disease recurrence had no significant effect on final visual prognosis and had no correlation with the morphological improvement during treatment, suggesting that follow-up for subsequent monitoring should be performed in all ICNV patients.

Relapse of choroidal neovascularization in Bietti's crystalline retinopathy following anti-vascular endothelial growth factor therapy: A case report.

Case Report: A Case of Cystoid Macular Edema in Retinitis Pigmentosa With Central Retinal Vein Occlusion

Evaluation of Efficacy and Recurrence for Anti-Vascular Endothelial Growth Factor Therapy in Idiopathic Choroidal Neovascularization

Sudden visual loss in the untreated eye of a patient with neovascular glaucoma following an intravitreal bevacizumab injection: A case report.

Punctate inner choroiditis and choroidal neovascular membrane formation following vitreoretinal surgery: A case report

Received anti-VEGF therapy in a patient with CRAO sparing the CLRA with subretinal fluid: A case report

Choroidal neovascularisation in a predicted female choroideraemia carrier treated with intravitreal anti-vascular endothelial growth factor

Bietti crystalline retinal dystrophy with subfoveal neurosensory detachment and congenital tortuosity of retinal vessels: case report

Outcome of Intravitreal Bevacizumab for Idiopathic Choroidal Neovascularization in a Chinese Population

Multimodal imaging features and genetic findings in Bietti crystalline dystrophy

The clinical observation of intravitreal Bevacizumab for recurrent idiopathic choroidal neoascularization

Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry

Choroidal neovascularization as first sign of Best's vitelliform dystrophy in a child

Atypical choroidal neovascular membrane

Rapid resolution of severe exudation in uveal effusion syndrome with anti-vascular endothelial growth factor alone in a case of bilateral nanophthalmos: a case report

Intravitreal bevacizumab injection on idiopathic choroidal neovascularization

Intravitreal anti-vascular endothelial growth factor in the treatment of idiopathic choroidal neovascularization:a retrospective analysis

Progression of macular retinoschisis following intravitreal aflibercept injection for myopic macular neovascularization—a case report and review of literature

A Case of Chorioretinitis with Retinal Angiomatous Proliferation

Intravitreal Bevacizumab (Avastin) for Myopic Choroidal NeovascularizationSix-Month Results of a Prospective Pilot Study

Multiple Choroidal Neovascularizations in Choroidal Osteoma Treated with Anti-VEGF Injections: A 6-Year Follow-Up Case Report